Browse by category

The last participant has been randomised and dosed in Amylyx Pharmaceuticals’ pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with an FDA Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicentre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gast

Amylyx Pharmaceuticals has represented analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational,...

Amylyx Pharmaceuticals has acquired avexitide from Eiger BioPharmaceuticals, an investigational, first-in-class glucagon-like peptide-1...

Phase 2b results of avexitide (Eiger BioPharmaceuticals) in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic...